Michael J. LaBarre

Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery

M. Printz, D. Kang, S. Knowles, 2021, Expert opinion on drug delivery.

Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration

B. Sugarman, M. Printz, D. Kang, 2022, The AAPS Journal.

Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration

B. Sugarman, M. Printz, D. Kang, 2022, The AAPS Journal.

Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.

J. Davies, L. Jiang, L. Pan, 2001, Biotechnology and bioengineering.

In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain.

P. Brams, P. Chinn, M. LaBarre, 2000, International journal of immunopharmacology.